ORGS — Orgenesis Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.56m
- $17.16m
- $1.04m
Orgenesis rises on FDA nod for device trial in COVID-19 patients
Brief: FDA Approves Orgenesis IDE For Pilot Clinical Trial
Brief: Orgenesis Files For Mixed Shelf Of Up To $100 Mln
Brief: Orgenesis Enters Into Collaboration Agreement With The Bambino Gesù Children's Hospital In Rome To Establish Point Of Care Cell And Gene Therapy Center
Brief: Orgenesis Enters Into Collaboration Agreement With Mida To Deploy Ompuls For Point-Of-Care Research And Development Of Promising Cell And Gene Therapies
Brief: Orgenesis Enters Second Phase Of Collaboration With Hospital Infantil Universitario Niño Jesús In Madrid
Brief: Orgenesis Says Signed Collaboration Agreement With Dong-A University Hospital In South Korea, And Cure Therapeutics
Brief: Orgenesis Files For Shelf Of Up To 4.8 Mln Shares By Selling Stockholders - SEC Filing
Brief: Orgenesis Q3 Revenue Rose 40% To $1.7 Million
U.S. STOCKS ON THE MOVE-Caravana, Vroom, Peabody Energy, Canadian Solar
U.S. STOCKS ON THE MOVE-Scorpio Bulkers, LifeSci Acquisition, Shutterstock, Intellia Therapeutics
U.S. STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group
U.S. STOCKS ON THE MOVE-Tesla, Nikola, Big Lots, Sogou
Orgenesis: Surges on deal to acquire Koligo Therapeutics
Brief: Orgenesis Selects Therapeutics Inc To Support Planned Study Of Genital Warts Drug
Brief: Orgenesis Q2 2020 Revenue Increases 55% Reflecting Progress Of Pocare Platform
Brief: Orgenesis To Collaborate With Educell To Conduct Clinical Validation Of Cell Therapies
Brief: Orgenesis Added To Russell 3000® Index
Brief: Orgenesis And Leidos Collaborate On Potential Treatment For Covid-19